Actively Recruiting
Good-first: B/F/TAF As First-line ART
Led by Affiliated Hospital of Nantong University · Updated on 2024-10-01
630
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
A
Affiliated Hospital of Nantong University
Lead Sponsor
N
Nantong Third Peoples Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a multicohort study conducted at Affiliated Hospital of Nantong University, and Nantong Third Peoples Hospital (Designated Hospital for HIV/AIDS Treatment of Nantong City), China. The study would involve 630 patients initiating HIV treatment, divided into six cohorts. The enrollment period for the prospective cohort is from July 2024 to June 2025, while the enrollment period for the retrospective cohort is from January 2020 to June 2023.
CONDITIONS
Official Title
Good-first: B/F/TAF As First-line ART
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (≥18 years) diagnosed with HIV/AIDS, ART-naive, from July 2024 to June 2025 (prospective) or January 2020 to June 2023 (retrospective).
- Eligible for ART initiation with B/F/TAF or previously treated with TDF+3TC+EFV or DTG/3TC.
- Willing to adhere to study procedures and follow-up visits or have complete electronic health records (EHRs).
You will not qualify if you...
- Severe renal impairment (creatinine clearance < 50 mL/min).
- Hepatitis B co-infection or severe hepatic impairment (Child-Pugh Class C).
- Active tuberculosis (TB).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nantong Third Peoples Hospital
Nantong, Jiangsu, China, 226006
Actively Recruiting
Research Team
G
Gang Qin, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here